Revance price target raised to $38 from $35 at Needham

Needham analyst Serge Belanger raised the firm’s price target on Revance to $38 from $35 and keeps a Buy rating on the shares. The company’s Q4 preliminary sales were "solid" as its management also provided an update on the Daxxify commercial launch, the analyst tells investors in a research note. Belanger adds that the $10.5M-$11.5M in preliminary Q4 Daxxify sales drove yesterday’s upside in the stock as little to no Daxxify sales were expected in the quarter.